Roche Holding Balance Sheet Health

Financial Health criteria checks 4/6

Roche Holding tiene unos fondos propios totales de CHF30.3B y una deuda total de CHF25.4B, lo que sitúa su ratio deuda/fondos propios en 83.7%. Sus activos y pasivos totales son CHF84.4B y CHF54.0B respectivamente. Roche Holding El EBIT de la empresa es de CHF19.6B, por lo que su ratio de cobertura de intereses es de 30.1. Su tesorería e inversiones a corto plazo ascienden a CHF7.5B.

Key information

88.0%

Debt to equity ratio

CHF29.28b

Debt

Interest coverage ratio	28.1x
Cash	CHF10.51b
Equity	CHF33.26b
Total liabilities	CHF57.21b
Total assets	CHF90.47b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Pasivos a corto plazo: RHHB.YLos activos a corto plazo (CHF31.0B) de la empresa superan a sus pasivos a corto plazo (CHF26.2B).

Pasivo a largo plazo: RHHB.YLos activos a corto plazo (CHF31.0B) superan a sus pasivos a largo plazo (CHF27.8B).

Debt to Equity History and Analysis

Nivel de deuda: La relación deuda neta-capital de RHHB.Y (58.9%) se considera alta.

Reducción de la deuda: RHHB.Yha pasado de 68.7% a 83.7% en los últimos 5 años.

Cobertura de la deuda: RHHB.YLa deuda de la empresa está bien cubierta por el flujo de caja operativo (67.5%).

Cobertura de intereses: RHHB.YLos pagos de intereses de su deuda están bien cubiertos por el EBIT (28.1x cobertura).

Balance Sheet

Discover healthy companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Roche Holding Balance Sheet Health

Financial Health criteria checks 4/6

Key information

Recent financial health updates

Recent updates

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Roche’S Alecensa Delivers Unprecedented Phase III Results for People with ALK-positive early-stage lung cancer

Roche Holding AG Tecentriq Becomes the First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Available to Patients in Great Britain, Reducing Treatment Time to Just Minutes

Roche Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

Roche Holding AG Confirms Earnings Guidance for the Year 2023

Roche Announces New Clinical and Real-World Data for Vabysmo at ASRS Reveal Improved Outcomes for People with Two Leading Causes of Vision Loss

Roivant Sciences Reportedly Near Deal to Sell Stomach Drug to Roche for over $7 Billion

Roche Announces Positive Phase III Results for Roche’s OCREVUS (ocrelizumab) Twice a Year, 10-minute Subcutaneous Injection in Patients with Multiple Sclerosis

European Commission Approves Roche Holding AG's Fixed-Term Columvi (Glofitamab) for People with Relapsed or Refractory Diffuse Large B-Cell L-Cell Lymphoma

Roche Receives FDA Clearance for Additional Alzheimer's Disease Cerebrospinal Fluid Assays, Supporting Timely Diagnosis and Treatment Decision-Making

Roche Looking to Sell or Shut Down Vacaville, California Plant

Roche Announces U.S. Food and Drug Administration Accepted Supplemental Biologics License Application for Vabysmo

Roche Announces Positive New Data from Two Global phase III studies, BALATON and COMINO

Roche Announces Positive Data from Global Phase III Programme for Crovalimab in PNH, A Rare Life-Threatening Blood Condition

Roche Holding AG Announces Executive Appointments

Roche Launches COVID-19 PCR Test to Detect the Fast Spreading XBB.1.5 Omicron Sub-Variant

Roche Announces the Phase III IMbrave050 Study Met Its Primary Endpoint of Recurrence-Free Survival (RFS) At the Prespecified Interim Analysis

Roche Announces the European Commission Approval of Xofluza for the Treatment and Prevention of Influenza in Children Aged One Year and Above

FDA approves Roche Holding AG’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma

Roche Presents New Data Demonstrating the Potential Benefit of Glofitamab and Lunsumio as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma

Roche Holding AG Announces its Alzheimer’s Disease Cerebrospinal Fluid (CSF) Assays Receive FDA Clearance, Supporting More Accurate and Timely Diagnosis

Roche Diagnostics North America Announces Brad Moore as President, Effective January 1, 2023

Roche Receives U.S. FDA Emergency Use Authorization for Its High-Throughput Test to Detect Monkeypox Virus

Roche Receives US Food and Drug Administration (FDA) Approval of VENTANA FOLR1 (FOLR1-2.1) RxDx Assay

Roche Launches Pilot Brand, Expands Retail Channels for COVID-19 at-Home Test

Roche Holding AG Announces STRONG-HF Study Results Demonstrate Clear Benefits for Acute Heart Failure Patients

Roche Introduces the navify Brand for Its Digital Health Solutions At HLTH 2022

Roche Introduces the Cobas 5800, A New Molecular Diagnostic System to Expand Access to PCR Testing in the U.S

Roche Holding AG Announces Positive Topline Results from Two Global Phase Iii Studies, BALATON and COMINO

Roche Holding Receives FDA Clearance for COVID-19 PCR Test for Use on Cobas 6800/8800 Systems

Roche Holding AG Provides Earnings Guidance for the Year 2022

Roche to Present New Ocrevus (Ocrelizumab) Data in Multiple Sclerosis and Continued Research into Neuromyelitis Optica Spectrum Disorder At Ectrims 2022

Roche Holding AG Announces New Two-Year Data from JEWELFISH Study Evaluating Evrysdi® (Risdiplam) in People with Type 1, 2 or 3 SMA Aged 6 Months to 60 Years at Time of Enrolment

Roche Launches PRAME (EPR20330) Antibody to Identify PRAME Protein Expression in Patients That May Have Melanoma

Roche Holding AG Receives FDA Approval for First Companion Diagnostic to Identify Patients with HER2 Low Metastatic Breast Cancer Eligible for Enhertu

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies